About Aptimmune Biologics
Aptimmune Biologics is a company based in Champaign (United States) founded in 2010.. Aptimmune Biologics has raised $11.05 million across 6 funding rounds from investors including United States Department of Agriculture, Arsenal Capital Partners and BioGenerator Ventures. The company has 3 employees as of December 31, 2024. Aptimmune Biologics offers products and services including Barricade R Platform and Swine Vaccines. Aptimmune Biologics operates in a competitive market with competitors including Merck Animal Health, TARGAN, Intervacc, Indian Immunologicals and VitamFero, among others.
- Headquarter Champaign, United States
- Employees 3 as on 31 Dec, 2024
-
Sectors
HealthcareAgriculture
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Aptimmune Biologics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$11.05 M (USD)
in 6 rounds
-
Latest Funding Round
- Investors
-
Employee Count
3
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aptimmune Biologics
Aptimmune Biologics offers a comprehensive portfolio of products and services, including Barricade R Platform and Swine Vaccines. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for developing vaccines against swine diseases like PRRSV.
Vaccines targeting IAV-S and ASFV in swine populations.
Unlock access to complete
Unlock access to complete
Leadership Team
4 people
Chairman Team
1 people
Senior Team
1 people
Founder Team
1 people
Management Team
1 people
Unlock access to complete
Funding Insights of Aptimmune Biologics
Aptimmune Biologics has successfully raised a total of $11.05M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Last Round
-
First Round
First Round
(09 Jul 2015)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2021 | Amount | Series B - Aptimmune Biologics | Valuation | BioGenerator |
|
| Jan, 2018 | Amount | Series B - Aptimmune Biologics | Valuation | St. Louis Arch Angels , Missouri Technology |
|
| Sep, 2017 | Amount | Grant - Aptimmune Biologics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Aptimmune Biologics
Aptimmune Biologics has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include United States Department of Agriculture, Arsenal Capital Partners and BioGenerator Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and acceleration are provided to life science startups.
|
Founded Year | Domain | Location | |
|
Early-stage businesses are funded by St. Louis Arch Angels.
|
Founded Year | Domain | Location | |
|
Tech companies focused VC firm operating across Missouri
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Aptimmune Biologics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Aptimmune Biologics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Aptimmune Biologics Comparisons
Competitors of Aptimmune Biologics
Aptimmune Biologics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck Animal Health, TARGAN, Intervacc, Indian Immunologicals and VitamFero, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Vaccine technology is developed and supplied for livestock animals.
|
|
| domain | founded_year | HQ Location |
Automated targeted vaccine systems for livestock and aquaculture are developed.
|
|
| domain | founded_year | HQ Location |
Recombinant vaccines for cattle, equine, and other livestock are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines for animal and human health are manufactured.
|
|
| domain | founded_year | HQ Location |
Offers patented immunostimulating vaccines for livestock.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Aptimmune Biologics
When was Aptimmune Biologics founded?
Aptimmune Biologics was founded in 2010 and raised its 1st funding round 5 years after it was founded.
Where is Aptimmune Biologics located?
Aptimmune Biologics is headquartered in Champaign, United States. It is registered at Champaign, Illinois, United States.
Is Aptimmune Biologics a funded company?
Aptimmune Biologics is a funded company, having raised a total of $11.05M across 6 funding rounds to date. The company's 1st funding round was a Grant of $600K, raised on Jul 09, 2015.
How many employees does Aptimmune Biologics have?
As of Dec 31, 2024, the latest employee count at Aptimmune Biologics is 3.
What does Aptimmune Biologics do?
Aptimmune Biologics was founded in 2010 in Champaign, United States, and operates in the biologics sector focused on animal health. Prophylactic vaccines against viral swine diseases, particularly Porcine Reproductive and Respiratory Syndrome (PRRS) virus, are developed and manufactured. Novel nasal delivery methods are employed, including a proprietary pig alveolar macrophage cell line known as ZMAC, to enhance vaccine efficacy.
Who are the top competitors of Aptimmune Biologics?
Aptimmune Biologics's top competitors include TARGAN, Merck Animal Health and Indian Immunologicals.
What products or services does Aptimmune Biologics offer?
Aptimmune Biologics offers Barricade R Platform and Swine Vaccines.
Who are Aptimmune Biologics's investors?
Aptimmune Biologics has 9 investors. Key investors include United States Department of Agriculture, Arsenal Capital Partners, BioGenerator Ventures, St. Louis Arch Angels, and Missouri Technology.